

PROLIGHT DIAGNOSTICS SHOWCASES PSYROS™ AT ADLM 2025 IN CHICAGO

Prolight Diagnostics AB will display a fully functioning commercial prototype of its groundbreaking Psyros Digital point of care IVD platform at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025, in Chicago July 27th–29th.

This marks the first public display of the company's fully functioning Psyros™ prototype, developed to deliver rapid, lab-quality results at the point of care. Compact, user-friendly, and highly versatile, the prototype embodies Prolight's mission to transform how and where diagnostics are delivered – bringing advanced testing closer to patients and clinicians.

"Presenting our commercial prototype at ADLM 2025 is a significant step forward," said Ulf Bladin, CEO at Prolight. "We are excited to demonstrate not just a concept, but a ready-to-scale solution designed to support faster clinical decisions and better patient outcomes."

Visitors to Prolight's booth will have the opportunity to get up close with the device and meet the team behind its development. The company is also inviting key potential partners, investors, and healthcare professionals to demonstrations of the instrument.

ADLM 2025 is the premier annual gathering for laboratory medicine professionals – combining a scientific educational conference, innovation showcase, and global networking opportunity.

Event Details:

ADLM 2025 (formerly AACC Annual Scientific Meeting & Clinical Lab Expo)

Location: Chicago, IL

Dates: 27th to 31st July, 2025

Booth #: DxPX Area Booth 09

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight Diagnostics showcases Psyros™ at ADLM 2025 in Chicago